Compare DVN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DVN | BIIB |
|---|---|---|
| Founded | 1971 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | DVN | BIIB |
|---|---|---|
| Price | $36.15 | $170.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 22 |
| Target Price | $43.53 | ★ $177.40 |
| AVG Volume (30 Days) | ★ 8.2M | 2.0M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 4.24 | ★ 10.97 |
| Revenue | ★ $16,554,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $13.09 | $3.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $8.71 | $15.68 |
| Revenue Growth | ★ 13.94 | 4.77 |
| 52 Week Low | $25.89 | $110.04 |
| 52 Week High | $38.88 | $185.17 |
| Indicator | DVN | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 47.81 |
| Support Level | $34.91 | $169.52 |
| Resistance Level | $37.04 | $175.94 |
| Average True Range (ATR) | 0.93 | 5.18 |
| MACD | -0.28 | -1.99 |
| Stochastic Oscillator | 33.58 | 10.97 |
Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2024, Devon reported net proved reserves of 2.2 billion barrels of oil equivalent. Net production averaged roughly 848,000 barrels of oil equivalent per day in 2024 at a ratio of 73% oil and natural gas liquids and 27% natural gas.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).